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Acute graft-versus-host disease (aGVHD) is mediated by allogeneic T cell responses. We hypothesized that
increases of peripheral bloodeactivated CD8þ effector memory T (TEM) cells would be observed after he-
matopoietic stem cell transplantation (HSCT) before onset of aGVHD symptoms. Blood was collected twice
weekly after HSCT for 7 weeks in 49 consecutive pediatric and adult HSCT recipients. Samples were incubated
with ﬂuorochrome-conjugated antibodies against CD45, CD3, CD8, CD38, CD45RA, and CCR7 and analyzed
using ﬂow cytometry. TEM cells were deﬁned as CD3þ CD8þCCR7 CD45RA lymphocytes. CD38 expression
was used as a marker of T cell activation. Patients were followed for 100 days for development of aGVHD.
Twenty-three patients developed grade 1 to 4 aGVHD at a median of 37 days (range, 15 to 79 days) after HCST.
Absolute CD38 bright CD8þ TEM of > 35 cells/mL predicted aGVHD at a median of 8 days (range, 1 to 34)
before aGVHD onset with a sensitivity of 82.6% and speciﬁcity of 91.6%. The cumulative incidence of aGVHD
was 90% in patients with absolute CD38 bright CD8þ TEM >35 cells/mL and 15% in patients without (P <
.0001). Quantiﬁcation of CD38 bright CD8þ TEM cells may predict aGVHD in children and young adult HSCT
recipients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION (Table 1) [4-15]. Thus, a need exists for novel, noninvasive
Acute graft-versus-host disease (aGVHD) is a signiﬁcant
complication of allogeneic hematopoietic stem cell trans-
plantation (HSCT) and is the leading cause of nonrelapse
mortality [1]. Approximately 35% to 50% of HSCT recipients
develop aGVHD; however, there are no validated predictive
blood biomarkers for aGVHD in clinical use [1,2]. The ability
to predict aGVHD before onset may allow for development of
pre-emptive therapeutic strategies that could potentially
reduce post-transplantation morbidity and mortality related
to aGVHD [3]. Various biomarkers in blood or urine have
been investigated, but their applicability is limited by sub-
optimal sensitivity or speciﬁcity, elevated cost of processing
samples, or lack of validation in large-scale clinical trialsdgments on page 1221.
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ty for Blood and Marrow Transplantation.biomarkers that can reliably predict aGVHD.
T cells are known to play a role in both acute and chronic
GVHD, but the exact subset of T cells implicated in the
pathogenesis of GVHD in humans remains unclear [16-19]. T
cells are classically divided into naïve and memory cells,
based on the presence or absence of previous antigen
encounter. After antigen exposure, naïve T cells have the
ability to expand and differentiate into memory T cells [20].
C-C chemokine receptor type 7 (CCR7, cluster of differentia-
tion 197) is a chemokine receptor that plays a role in homing
of T cells to secondary lymphoid organs. The presence or
absence of its expression divides human memory T cells into
2 functionally distinct subsets [21]. Central memory T cells
(CCR7þ) do not possess immediate effector function [20].
These are usually found in lymphoid tissues and upon
stimulation, differentiate into CCR7 effector cells [21].
Effector memory T cells (TEM) (CCR7) are excluded from
lymphoid tissues, express receptors for migration to
inﬂamed tissues, and display immediate effector function
[21]. These cells rapidly produce effector cytokines or express
perforin granules [21].
Table 1
Biomarkers Evaluated for Prediction of aGVHD
Author Biomarker Day of Measurement No. of Patients Sensitivity Speciﬁcity AUC
Miyamoto et al. sIL2r Day þ3 30 Not mentioned Not mentioned
Kitko et al. TNFr1 Day þ7 82 children 31% 82% .63
Willems et al. TNFr1 in nonmyeloablative
conditioning
Day þ7/baseline ratio 106 Hazard ratio, 2.1; P ¼ .01
August et al. sIL2rþ sCD8þ sTNFr1 Day þ15 62 64% 76% .77
Liu et al. Plasma IL-6 Day 1-21 after transplantation 101 Not mentioned
Xiao B et al. Combined 4 miRNA panel 2 weeks after HSCT 196 92% 62% .80
Paczesny et al. IL2Ra, TNFr1, elaﬁn Preconditioning, day þ7 and day
þ14 after HSCT
Training ¼ 342
Validation ¼ 142
75% 57%
Kaiser T et al. 16 urine polypeptides Twice weekly before conditioning
until discharge
35 100% 82%
Thiant et al. IL7 (myeloablative
conditioning)
Day þ14 40 Hazard ratio, 5.38; P ¼ .022
Thiant et al. IL7 (reduced-intensity
conditioning)
Day þ30 45 Hazard ratio, 1.221; P ¼ .002
Choi et al. sTNFr1 in myeloablative
conditioning
Before transplantation and day þ7 438 38% 83%
Vander Lugt et al. ST2 Day þ14 673 Predictive of nonrelapse mortality after
transplantation
AUC indicates area under the curve.
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naïve T cells cause GVHD [22-24]. In addition, CD8þ central
memory cells may also be able to mediate aGVHD [16]. In
contrast, TEM cannot cause murine aGVHD unless previously
primed [25,26]. After allogeneicHSCT in humans, it is possible
that aGVHD responses evolve as naïve T cells are activated by
alloantigens and then proliferate and differentiate into
memory subsets with effector functions. The recent obser-
vation in humans of increased numbers of CD4þ and CD8þ
TEM cells at day þ28 after HSCT in patients who developed
aGVHD suggests that TEMs play a role in aGVHD [27]. Inter-
estingly, 2 early ﬂow cytometric human studies thatFigure 1. Representative dots plots demonstrating gating strategy for CD38 bright CD8
not develop aGVHD (middle panel), and a patient after HSCT who subsequently deve
gate, based on CD45 intensity and side light scatter characteristics.examined total CD4þ and CD8þ T cell populations in patients
after allogeneic HSCT noted a predominant association of
aGVHDwith peripheral blood CD8þ Tcell populations orwith
decreasing CD4 to CD8 ratios, suggesting that CD8þ T cell
expansion plays an important role in human aGVHD [28,29].
Previous human studies have also attempted to discover a
T cell surface activation marker that correlates with aGVHD
without success [30]. Cluster of differentiation 38 (CD38) is
located on human chromosome 4 (4p15) [31]. CD38 plays
dual roles as receptor and ectoenzyme and regulates activ-
ities related to signaling and cell homeostasis [31]. CD38 was
initially thought to be expressed by thymocytes andþ TEM cells in a healthy adult control (top panel), a patient after HSCT who did
loped aGVHD (bottom panel). Analysis was restricted to an initial lymphocyte
Table 2
Demographics of Patients with and without aGVHD
Factor GVHD n ¼ 23 No GVHD
n ¼ 24
P Value
Age, median (range), yr 13.5 (1-33) 7.5 (.25-25.5) .07
Diagnosis .02
Malignancy 12 (53%) 3 (12%)
Primary immune deﬁciency 7 (31%) 11 (45%)
Hemoglobinopathy 1 (4%) 1 (4%)
Marrow failure 2 (8%) 8 (3%)
Metabolic disorder 1 (4%) 1 (4%)
Preparative regimen .02
Myeloablative 14 (61%) 6 (25%)
Reduced intensity 9 (39%) 18 (75%)
Serotherapy in conditioning .004
Alemtuzumab 3 (13%) 16 (66%)
Antithymocyte globulin 15 (65%) 5 (20%)
HLA match .07
8/8 17 (74%) 22 (92%)
7/8 6 (26%) 1 (4%)
6/8 0 (0%) 1 (4%)
Relation .13
Related 6 (26%) 12 (50%)
Unrelated 17 (74%) 12 (50%)
Stem cell source 1.00
Bone marrow 22 (96%) 22 (92%)
PBSC 1 (4%) 1 (4%)
Cord blood 0 (0%) 1 (4%)
GVHD prophylaxis .22
CSA/MP 9 (39%) 16 (67%)
CSA/MTX 8 (35%) 4 (17%)
CSA/MMF 4 (18%) 2 (8%)
Tacrolimus/MP/MVR 1 (4%) 0 (0%)
MMF 0 (0%) 1 (4%)
CSA 1 (4%) 1 (4%)
Cell dose, median (range)
TNC (108/kg) 6.4 (2.5-12.6) 6.6 (.7-19.4) .21
CD34 (106/kg) 5.3 (1.1-16) 5.1 (.3-20.1) 4.60
CD3 (107/kg) 7.3 (2.3-28) 6.0 (2.3-20.2) .51
PBSC indicates peripheral blood stem cells; CSA, cyclosporine A; MP,
methylprednisolone; MTX, methotrexate; MMF, mycophenolate mofetil;
MVR, maraviroc; TNC, total nucleated cell.
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vation and proliferation of humanTcells [32,33], but it is now
known to be present throughout the immune system with
varying levels of expression [31]. CD38 plays a signiﬁcant
role in various disease states, namely chronic lymphocytic
leukemia [34], ovarian cancer [35], and multiple myeloma
[31], and its presence is associated with clinically aggressive
disease and poor prognosis. In addition, high ratios of CD8þ
CD38þ T lymphocytes predict disease progression in HIV
infected adults [36,37]. Perhaps, the most relevant role of
CD38 lies in its interaction with platelet endothelial cell
adhesion molecule-1, which is crucial for leukocyte migra-
tion through the endothelium [38]. The role of CD38 in
aGVHD has not been explored yet, but it is possible that
upregulation of CD38 in activated TEMs could be an impor-
tant step in trafﬁcking of these cells to target organs.
To test our hypothesis that peripheral blood CD38 bright
CD8þ TEM cells increase in patients with aGVHD before
clinical symptoms and can predict aGVHD, we serially
quantiﬁed CD38 bright CD8þ TEM populations in pediatric
and young adult allogeneic HSCT patients. We found that
CD38 bright CD8þ TEM cells were readily detected in pa-
tients before aGVHD and that peripheral blood elevation of
these cells could be used to predict onset of aGVHD.
METHODS
Patients and Transplantation Procedures
Institutional review board approval was granted for this study and
participants gave informed consent. Twice weekly blood samples were
obtained from 49 consecutive pediatric and young adult patients who un-
derwent allogeneic HSCT at our center between April, 2013 and April, 2014
and received a T cellereplete graft. The choice of conditioning regimen and
GVHD prophylaxis was made by the treating physician. All patients received
supportive care measures, including nutritional support, intravenous
immunoglobulin replacement, antifungal, antiviral, and antiePneumocystis
jerovecii prophylaxis, as part of routine clinical care. Clinical informationwas
prospectively collected until day þ100, including date of onset of aGVHD,
stage and grade of aGVHD, and viral reactivation with Epstein-Barr virus,
adenovirus, and cytomegalovirus. aGVHD was diagnosed clinically by the
treating physician and supported with biopsies whenever indicated. aGVHD
was graded using the modiﬁed Glucksberg criteria [39].
Quantiﬁcation of Peripheral Blood CD38 Bright CD8þ TEM
Venous blood samples were prospectively collected once before trans-
plantation and twice weekly for 7 weeks after stem cell infusion for char-
acterization of T cell phenotype. Freshly obtained blood samples were
incubated with ﬂuorochrome-conjugated monoclonal antibodies directed
against CD3 (Biolegend, San Diego, CA), CD38 (eBioscience, San Diego, CA)
CD45, CD8, CD45RA, and CCR7 (BD Biosciences, San Jose, CA), followed by
red cell lysis and ﬁxation. Samples were analyzed by ﬂow cytometry on a
FACS Canto II ﬂowcytometer (BD Biosciences). Datawere analyzed using FCS
Express version 4.0 (De Novo Software). CD8þ TEM cell populations were
deﬁned as CD3þ CD8þ lymphocytes that lacked expression of CD45RA and
CCR7. Gating strategy is shown in Figure 1. The absolute whole blood CD8þ T
cell count was calculated from the percentage of CD3þ CD8þ lymphocytes
within the lymphocyte gate (as determined by CD45 intensity and side light
scatter characteristics) multiplied by the absolute lymphocyte count. The
absolute lymphocyte count was obtained from the complete blood count
from the same day as ﬂow cytometry sample collection, in the clinical he-
matology lab at Cincinnati Children’s Hospital Medical Center. Absolute
CD38 bright CD8þ TEM cell counts were calculated as percentages of the
absolute CD8þ T cell count.
Statistics
For sample size calculations, we used the Fisher exact test. For com-
parisons of patient demographic and transplantation characteristics, we
used the 2-sided Student t-test to compare age and Fisher exact test to
compare categorical variables. A receiver operating characteristic analysis
was performed to estimate area under the curve and determine the opti-
mum threshold value of CD38 bright CD8þ TEM elevation to predict aGVHD.
Evaluations were performed using XLSTAT software (Addinsoft, Paris,
France). CD38 bright CD8þ TEM cells exhibited a high incidence rate of zeros.
To account for this, and to account for the intensity of the nonzero levels, azero-inﬂated gamma regression was used for CD38 bright CD8þ TEMs at
each time point. Standard errors of the mean were found by applying the
deltamethod to Fisher’s informationmatrix. Corresponding 2-sided P values
were generated from the t-distribution. All computations were done in SAS
9.3 (SAS Institute, Cary, NC). Gray’s method was used to generate cumulative
incidence curves to compare the cumulative incidence of aGVHD in patients
with and without elevation of CD38 bright CD8þ TEM above the threshold
value using the cmprsk package in R (R Foundation for Statistical
Computing, Vienna, Austria). As only 1 patient died during study follow-up
and none experienced a disease relapse, no competing risk analysis was
performed. Statistical signiﬁcance was considered for P < .05.RESULTS
Patients
Forty-nine consecutive pediatric and young adult alloge-
neic HSCT recipients were enrolled for study. Two patients
were excluded from analysis as they did not have peripheral
blood samples the week before diagnosis of aGVHD.
Demographic and transplantation information for the
remaining 47 patients are summarized in Table 2. The me-
dian age of patients who developed aGVHD was 13.5 years
(range, 1 to 33 years) compared with 7.5 years (range, .25 to
25.5 years) in the non-aGVHD group (P ¼ .07). Fifty-three
percent of patients in the aGVHD group underwent trans-
plantation for an underlying diagnosis of a malignancy,
whereas 12% of patients underwent transplantation for a
malignancy in the non-aGVHD group (P ¼ .02). Sixty-one
percent of patients in the aGVHD group received a myeloa-
blative preparative regimen compared with 25% of patients
Table 3
Grade and Timing of aGVHD Relative to Absolute CD38 Bright CD8þTEM cells/mL before Onset of aGVHD
Patient Maximum Absolute
CD38 Bright CD8þ
TEM (cells/mL)
Percentage of CD38
Bright CD8þ TEM Cells
Corresponding
to the Maximum
Absolute Value (%)
Timing of Maximum
Absolute CD38 Bright
CD8þ TEM
(Day after HSCT)
Onset of aGVHD
(Day after HSCT)
Onset of CD38 Bright
CD8þ TEM >35 cells/mL
(Day after HSCT)
Maximum Grade
of aGVHD
Organ(s)
Involved
1 64 77 26 33 26 1 Skin
2 69 92 48 58 37 3 GI, liver
3 32 88 34 41 34 1 Skin
4 304 87 34 47 20 1 Skin
5 231 98 7 34 7 1 Skin
6 41 84 24 34 24 2 Skin
7 99 99 25 32 25 4 Skin, liver
8 98 99 16 23 16 3 Skin, GI
9 90 96 52 69 17 3 Skin, liver
10 162 98 37 52 20 3 Skin, GI, liver
11 42 82 33 42 33 3 Skin, GI
12 36 92 11 15 11 4 Skin, GI
13 82 96 15 29 15 4 GI
14 37 98 43 44 12 2 Skin
15 151 99 45 79 15 3 Skin, GI
16 63 95 23 33 23 4 Skin, GI
17 47 97 25 31 25 1 Skin
18 87 82 17 18 17 3 GI
19 69 86 56 59 56 1 Skin
20 2 87 25 28 NA 1 Skin
21 12 90 36 37 NA 1 Skin
22 70 99 28 38 21 1 Skin
23 128 97 42 45 28 3 Skin, GI
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patients in the non-GVHD group received a graft from an 8/8
HLAematched related or unrelated donor, whereas 74% of
patients in the aGVHD group received a graft from a fully
matched donor (P ¼ .07). Over 90% of patients in both groups
received bone marrow grafts (P ¼ 1.00).Development of aGVHD
Grade 1 (n¼ 9), grade 2 (n¼ 2), grade 3 (n¼ 8), and grade
4 (n ¼ 4) aGVHD were diagnosed in 23 patients at a median
of 37 days after HSCT (range, 15 to 79 days), as shown in
Table 3. Organ(s) of involvement included isolated skin
GVHD (n ¼ 11); isolated gastrointestinal (GI) GVHD (n ¼ 2);Figure 2. Kinetics of the average CD38 bright CD8þ TEM cells/mL shown twice weekly
did not develop acute graft-versus-host disease. *P < .05. The error bars represent stskin and visceral (GI or liver) GVHD (n ¼ 8); GI and liver
GVHD (n ¼ 1); and skin, liver, and GI GVHD (n ¼ 1).Quantiﬁcation of CD38 Bright CD8þ TEM Cells before
aGVHD
Increased values of peripheral blood CD38 bright CD8þ
TEM cells were observed in patients who subsequently
developed aGVHD (Figure 2). The levels of elevation during
weeks 4 to 7 were signiﬁcantly higher for patients who
developed aGVHD compared with patients who did not
develop aGVHD (P < .05). The maximum average absolute
CD38 bright CD8þ TEM cell count was 86  15.1 cells/mL in
patients before developing aGVHD, compared with 27  14.2
cells/mL in patients who did not develop aGVHD (P < .0001).in patients who developed acute graft versus host disease and in patients who
andard error of mean.
Figure 3. (A) Receiver operating characteristic curve analysis showing area under the characteristic curve of .859 for CD38 bright CD8þ TEM cells/mL as a predictor of
aGVHD. (B) Receiver operating characteristic curve analysis of grades 3 and 4 aGVHD versus grades 0 to 2 aGVHD showing an area under the curve of .850.
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CD8þ TEM cells was observed at a median of 8 days (range, 1
to 34 days) before onset of clinical aGVHD. We did not
observe an association between the extent of TEM elevation
and the grade of aGVHD (data not shown).Diagnostic Accuracy
A receiver operating characteristic curve demonstrated an
area under the curve of .859 (Figure 3A) and revealed that an
optimum threshold value of absolute CD38 bright CD8þ TEM
greater than 35 cells/mL was predictive of aGVHD with a
Figure 4. Probability of developing any grade of aGVHD (A) or grades 3 and 4
aGVHD (B) in patients who demonstrate absolute CD38 bright CD8þ TEM cells/
mL to >35 versus 35.
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patients with aGVHD developed an absolute CD38 bright
CD8þ TEM>35 cells/mL at a median of 10 days (range, 1 to 64
days) before onset of aGVHD. The positive and negative
predictive values were 90.5% and 84.6%, respectively. The
diagnostic accuracy was calculated to be 87%. When patients
with grades 3 and 4 aGVHD were compared with patients
with grades 0 to 2 aGVHD, the receiver operating charac-
teristic curve analysis revealed an area under the curve of
.850 (Figure 3B). Using the previously mentioned optimal
threshold value of>35 cells/mL, the sensitivity and speciﬁcity
were 91.7% and 74.3%, respectively. The cumulative incidence
of day þ100 aGVHD in patients who demonstrated absolute
CD38 bright CD8þ TEM cells> 35 cells/mL was 90%, compared
with 15% in patients who did not demonstrate values above
35/mL (P < .0001) (Figure 4). The cumulative incidence of
day þ100 aGVHD of grades 3 and 4 in patients who
demonstrated absolute CD38 bright CD8þ TEM cells > 35
cells/mL was 52%, compared with 4% in patients who did not
demonstrate values above 35/mL (P ¼ .0002).
Occurrence of Viral Reactivation
Viral infection is known to cause TEM cell expansion [40],
so we compared the incidence of Epstein-Barr virus, cyto-
megalovirus, and adenovirus reactivation between patients
with and without aGVHD to ensure that our results were not
inﬂuenced by viral-mediated TEM cell expansion (Table 4).
The occurrence of viremia(s) was documented until
day þ100 if no aGVHD were observed or until a diagnosis of
aGVHD was made and immunosuppressive treatment was
started. No statistically signiﬁcant differences were observed
between groups (Table 4). Notably, in patients who did not
develop aGVHD but did develop viremia (n ¼ 9), absolute
CD38 bright TEM > 35 cells/mL occurred in only 1 patient. All
remaining patients who developed viremia but not aGVHD
(n ¼ 8) maintained CD38 bright TEM populations of 35 cells/
mL or less.
DISCUSSION
Here we present data on 47 pediatric allogeneic
hematopoietic stem cell transplant recipients and show that
increases of CD38 bright CD8þ TEM cells to greater than 35
cells/mL predicted the onset of aGVHD approximately 1 week
before clinical symptoms, with a sensitivity of 82.6%, a
speciﬁcity of 91.7%, a positive predictive value of 90.5%, a
negative predictive value of 84.6%, and a diagnostic accuracy
of 87%. To our knowledge, this is the ﬁrst report demon-
strating the role of CD38 bright CD8þ TEM cells as a predic-
tive biomarker in aGVHD. The correlation between
development of aGVHD and changes in other T cell sub-
populations preceding onset of clinical symptoms has been
described in the past but have generally lacked relevant
levels of diagnostic screening accuracy [30]. A recent study in
over 200 adult stem cell transplant recipients demonstrated
elevated effector memory CD8þ T cells on day þ28 after
transplantation before aGVHD [27]. An earlier study by
Soiffer et al. described an increase in percentages and abso-
lute CD8þ T cell numbers that correlated with onset of
aGVHD in CD6-depleted bone marrow recipients [28]. Gra-
tama et al. described the correlation of early decreasing CD4
to CD8 ratios with increased risk of developing aGVHD in
adult bone marrow transplant recipients [29]. These reports
further corroborate the ability to use peripheral blood ﬂow
cytometric screening to identify patients at high risk of
developing aGVHD. The quantiﬁcation of CD38 bright CD8þTEM cells appears to elevate this approach to achieve clini-
cally relevant levels of accuracy.
Our observations also might offer some novel insights
into the biology of aGVHD. Naïve T cells travel to secondary
lymphoid organs where they interact with antigen-
presenting cells. Once activated, these T cells proliferate
and generate effector cells that can migrate to inﬂamed
tissues [21]. A number of chemokine receptors and adhesion
molecules are involved in lymphocyte migration to second-
ary lymphoid organs or to peripheral tissues under homeo-
static or inﬂammatory conditions. CCR7 memory T cells
express high levels of tissue-speciﬁc receptors such as
CD103, CLA, and beta 1 and 2 integrins, which are vital for
migration to inﬂamed tissues [41,42]. Receptors of inﬂam-
matory chemokines such as CCR1, CCR3, and CCR5 are known
to be selectively expressed in the effector memory subset
[21]. As CD38 interacts with platelet endothelial cell adhe-
sion molecule-1 and is the ﬁrst step in leukocyte migration,
the increased expression of CD38 on CD8þ TEM cells might
be related to trafﬁcking of these cells to target organs [31].
Table 4
Occurrence of Viral Reactivation after HSCT
Viral Reactivation after HCT aGVHD
(n ¼ 23)
No aGVHD
(n ¼ 24)
P Value
Epstein-Barr virus 5 (21%) 7 (29%) .74
Adenovirus 0 (0%) 3 (12.5%) .23
Cytomegalovirus 1 (4%) 5 (20%) .18
The occurrence of viremia(s) was documented until day þ100 if no aGVHD
was observed, or until a diagnosis of aGVHD was made and immunosup-
pressive treatment was started.
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role of CD38 in the pathophysiology of aGVHD. As disruption
of chemokines, such as CCR5, involved in T cell trafﬁcking to
target organs is an effective strategy in preventing aGVHD
[43], it is conceivable that as anti-CD38 therapies become
more available, these may present an attractive therapeutic
option for future consideration.
Our method of screening for aGVHD demonstrates a shift
in the paradigm of identifying aGVHD biomarkers. Our
approach takes into account the very dynamic nature of
aGVHD onset and diagnosis by prospectively sampling pe-
ripheral blood twice weekly after stem cell infusion, akin to
viral surveillance in the post-transplantation period. This
methodology was feasible in our patient population and the
ﬂowcytometry assay was rapid and, likely, easy to perform at
most clinical facilities with ﬂow cytometry expertise.
Our study does have some limitations. We recognize that
our sample size is small and that our ﬁndings need to be
validated in larger number of patients and to deﬁne a more
deﬁnitive optimum threshold to use to identify patients at
risk. Our small sample size did not allow us to adjust for
covariates, such as age, underlying diagnosis, preparative
regimen, HLAmatch, and age-related variations in the rate of
immune recovery, which could alter our study conclusions.
Although absolute CD38 bright CD8þ TEM cell expansion
appears to be predictive of onset of aGVHD, wewere not able
to predict severity of aGVHD in the current analysis. It is our
hope that future larger studies will reveal strategies that can
be used to stratify patients at higher risk of grades 3 and 4
GVHD and/or steroid-refractory aGVHD.
In conclusion, we have observed that peripheral blood
CD38 bright CD8þ TEM cells can predict aGVHD with high
sensitivity and speciﬁcity in pediatric and young adult HSCT
recipients. A subsequent large-scale trial is currently in
progress to further validate this novel observation and better
deﬁne a ﬁrm threshold value. Studies exploring functional
characteristics of these cells are also being carefully con-
ducted to shed further insight into the biology of aGVHD.
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